These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

315 related items for PubMed ID: 23404639

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Nafamostat mesilate as an anticoagulant during continuous veno-venous hemodialysis: a three-year retrospective cohort study.
    Maruyama Y, Yoshida H, Uchino S, Yokoyama K, Yamamoto H, Takinami M, Hosoya T.
    Int J Artif Organs; 2011 Jul; 34(7):571-6. PubMed ID: 21786254
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Comparison of nafamostat mesilate and unfractionated heparin as anticoagulants during continuous renal replacement therapy.
    Makino S, Egi M, Kita H, Miyatake Y, Kubota K, Mizobuchi S.
    Int J Artif Organs; 2016 Jan; 39(1):16-21. PubMed ID: 26868216
    [Abstract] [Full Text] [Related]

  • 5. The role of nafamostat mesylate in continuous renal replacement therapy among patients at high risk of bleeding.
    Baek NN, Jang HR, Huh W, Kim YG, Kim DJ, Oh HY, Lee JE.
    Ren Fail; 2012 Jan; 34(3):279-85. PubMed ID: 22251267
    [Abstract] [Full Text] [Related]

  • 6. Nafamostat Mesilate as an Anticoagulant During Continuous Renal Replacement Therapy in Patients With High Bleeding Risk: A Randomized Clinical Trial.
    Choi JY, Kang YJ, Jang HM, Jung HY, Cho JH, Park SH, Kim YL, Kim CD.
    Medicine (Baltimore); 2015 Dec; 94(52):e2392. PubMed ID: 26717390
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Association between Intra-Circuit Activated Clotting Time and Incidence of Bleeding Complications during Continuous Renal Replacement Therapy using Nafamostat Mesilate: a Retrospective Pilot Observational Study.
    Miyatake Y, Makino S, Kubota K, Egi M, Mizobuchi S.
    Kobe J Med Sci; 2017 Aug 30; 63(1):E30-E36. PubMed ID: 29434171
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Is regional citrate superior to systemic heparin anticoagulation for continuous renal replacement therapy? A prospective observational study in an adult regional critical care system.
    Bagshaw SM, Laupland KB, Boiteau PJ, Godinez-Luna T.
    J Crit Care; 2005 Jun 30; 20(2):155-61. PubMed ID: 16139156
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and safety of citrate-based anticoagulation compared to heparin in patients with acute kidney injury requiring continuous renal replacement therapy: a randomized controlled trial.
    Stucker F, Ponte B, Tataw J, Martin PY, Wozniak H, Pugin J, Saudan P.
    Crit Care; 2015 Mar 18; 19(1):91. PubMed ID: 25881975
    [Abstract] [Full Text] [Related]

  • 12. Filter Lifespan, Treatment Effect, and Influencing Factors of Continuous Renal Replacement Therapy for Severe Burn Patients.
    Yue Q, Wu H, Xi M, Li F, Li T, Li Y.
    J Burn Care Res; 2024 May 06; 45(3):764-770. PubMed ID: 38113522
    [Abstract] [Full Text] [Related]

  • 13. Continuous renal replacement therapies: anticoagulation in the critically ill at high risk of bleeding.
    Morabito S, Guzzo I, Solazzo A, Muzi L, Luciani R, Pierucci A.
    J Nephrol; 2003 May 06; 16(4):566-71. PubMed ID: 14696760
    [Abstract] [Full Text] [Related]

  • 14. Citrate versus heparin anticoagulation in continuous renal replacement therapy in small children.
    Raymakers-Janssen PAMA, Lilien M, van Kessel IA, Veldhoen ES, Wösten-van Asperen RM, van Gestel JPJ.
    Pediatr Nephrol; 2017 Oct 06; 32(10):1971-1978. PubMed ID: 28578542
    [Abstract] [Full Text] [Related]

  • 15. Comparison of nafamostat mesilate to citrate anticoagulation in pediatric continuous kidney replacement therapy.
    Miyaji MJ, Ide K, Takashima K, Maeno M, Krallman KA, Lazear D, Goldstein SL.
    Pediatr Nephrol; 2022 Nov 06; 37(11):2733-2742. PubMed ID: 35348901
    [Abstract] [Full Text] [Related]

  • 16. Nafamostat mesilate as a regional anticoagulant in patients with bleeding complications during extracorporeal membrane oxygenation.
    Park JH, Her C, Min HK, Kim DK, Park SH, Jang HJ.
    Int J Artif Organs; 2015 Nov 06; 38(11):595-9. PubMed ID: 26728787
    [Abstract] [Full Text] [Related]

  • 17. [Safety and efficacy of regional citrate anticoagulation in continuous renal replacement therapy in the presence of acute kidney injury after hepatectomy].
    Zhang C, Lin T, Zhang J, Liang H, Di Y, Li N, Gao J, Wang W, Liu S, Wang Z, Jiang H, Liu C.
    Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2018 Aug 06; 30(8):777-782. PubMed ID: 30220281
    [Abstract] [Full Text] [Related]

  • 18. Nafamostat mesilate, as a treatment for heparin resistance, is not associated with perioperative ischemic stroke in patients undergoing cardiac surgery with cardiopulmonary bypass.
    Kikura M, Tanaka K, Hiraiwa T, Tanaka K.
    J Cardiothorac Vasc Anesth; 2012 Apr 06; 26(2):239-44. PubMed ID: 22019206
    [Abstract] [Full Text] [Related]

  • 19. Unfractionated heparin versus nafamostat mesylate for anticoagulation during continuous kidney replacement therapy: an observational study.
    Kameda S, Fujii T, Ikeda J, Kageyama A, Takagi T, Miyayama N, Asano K, Endo A, Uezono S.
    BMC Nephrol; 2023 Jan 16; 24(1):12. PubMed ID: 36642717
    [Abstract] [Full Text] [Related]

  • 20. Anticoagulation During Extracorporeal Membrane Oxygenation; Nafamostat Mesilate Versus Heparin.
    Lim JY, Kim JB, Choo SJ, Chung CH, Lee JW, Jung SH.
    Ann Thorac Surg; 2016 Aug 16; 102(2):534-9. PubMed ID: 27083248
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.